Pharmaceutical industry – Page 25
-
NewsApotex chief executive steps down amid tumult at generics firm
President and chief executive of Canada’s biggest generic drugmaker resigns the same day that police announce its founder and his wife were murdered
-
OpinionWhy modern chemists need to think big
The lessons we can learn from the larger reaction scales of the past
-
BusinessCelgene takes a punt on M&A
Cancer specialist bags Juno therapeutics and Impact Biomedicines
-
BusinessFDA new drug approvals more than doubled in 2017
The FDA approved 46 new drugs last year – the highest number in over two decades – due to factors like streamlined policies at the agency
-
Research1500 reactions per day go with the flow
Automated flow chemistry system puts high-speed spin on drug discovery
-
BusinessNon-profit generic drug company created
Intermountain Healthcare is leading an effort in the US to prevent drug shortages and end their skyrocketing prices
-
NewsUK drug discovery model must ‘break and change’
Report calls for joined-up approach that brings together charities, industry and universities
-
BusinessDementia slips down pharma agenda
Pfizer, Shire, Acorda and Axovant rethink their neuroscience strategies
-
NewsThe latest lethal injection row explained
Two US states plan to use untried drugs to execute prisoners
-
BusinessTeva to cut 14,000 jobs
Saddled with debt in an increasingly competitive generic drug industry, the Israel-headquartered giant begins a difficult transformation
-
OpinionFor the sake of argument
It’s important to recognise which disputes can actually be resolved by science
-
ResearchSuzuki–Miyaura–hydrogenation targets 3D drugs
Researchers design a new pathway to make sp3 enriched drug molecules
-
BusinessPharmaceuticals roundup 2017
Political influence has strongly shaped industry activity in the past year
-
BusinessBayer and J&J lose first blood thinner lawsuit
US jury fines Xarelto makers $27.8 million for downplaying drug risks
-
BusinessMerck & Co and Qiagen to build UK research hubs
Almost 2000 jobs to be created at research centres in Manchester and London
-
BusinessEuropean drug regulator heads to Amsterdam
Brexit drives EMA to relocate, taking hundreds of jobs and significant expertise away from UK
-
OpinionBeyond buckets and batches
Embracing flow chemistry means leaving behind some faithful friends
-
BusinessTargeting rare diseases
Is working on genetic mutations that affect only a few in every thousand people risky?
-
BusinessBayer forms cancer-drug partnership with Loxo
Alliance could see Loxo net up to $1.55bn in upfront and milestone payments
-
FeatureStaying one step ahead of the game
Clare Sansom examines the need for agile drug development when tackling emerging viral disease outbreaks